Arcus Biosciences, Inc. — Earnings Quality Grade D
RCUS · Healthcare
Significant concerns
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 16 days, change -12 days YoY
AR growth -45.0% vs revenue growth -4.3%
Revenue -4.3%, CFFO -183.5%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -66.7% vs revenue -4.3%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 1.37. Profits backed by cash
FCF is negative ($-0.5B)
Accruals ratio = 11.3%. Exceeds 10%
Cash $1.0B covers debt $0.1B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -48.2x (<2x). Financial stress
Other assets -13.7% vs revenue -4.3%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor RCUS continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25